126 related articles for article (PubMed ID: 3125115)
21. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).
Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S
Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929
[TBL] [Abstract][Full Text] [Related]
22. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
[TBL] [Abstract][Full Text] [Related]
23. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic.
da Costa MAC; Krum LK; Geraldino JD; Schafranski MD; Gomes RZ; Reis ES
Braz J Cardiovasc Surg; 2016; 31(3):239-245. PubMed ID: 27737407
[TBL] [Abstract][Full Text] [Related]
25. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.
Ruiz-Irastorza G; Khamashta MA; Hunt BJ; Escudero A; Cuadrado MJ; Hughes GR
Arch Intern Med; 2002 May; 162(10):1164-9. PubMed ID: 12020188
[TBL] [Abstract][Full Text] [Related]
26. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
[TBL] [Abstract][Full Text] [Related]
27. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Healey JS; Eikelboom J; Douketis J; Wallentin L; Oldgren J; Yang S; Themeles E; Heidbuchel H; Avezum A; Reilly P; Connolly SJ; Yusuf S; Ezekowitz M;
Circulation; 2012 Jul; 126(3):343-8. PubMed ID: 22700854
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.
Linkins LA; Choi PT; Douketis JD
Ann Intern Med; 2003 Dec; 139(11):893-900. PubMed ID: 14644891
[TBL] [Abstract][Full Text] [Related]
29. Optimal oral anticoagulant therapy in patients with mechanical heart valves.
Cannegieter SC; Rosendaal FR; Wintzen AR; van der Meer FJ; Vandenbroucke JP; Briët E
N Engl J Med; 1995 Jul; 333(1):11-7. PubMed ID: 7776988
[TBL] [Abstract][Full Text] [Related]
30. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy.
Chan A; Woodruff RK
Aust N Z J Med; 1992 Apr; 22(2):119-22. PubMed ID: 1530532
[TBL] [Abstract][Full Text] [Related]
31. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
[TBL] [Abstract][Full Text] [Related]
32. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
[TBL] [Abstract][Full Text] [Related]
33. Oral anticoagulation therapy in pediatric patients: a prospective study.
Andrew M; Marzinotto V; Brooker LA; Adams M; Ginsberg J; Freedom R; Williams W
Thromb Haemost; 1994 Mar; 71(3):265-9. PubMed ID: 8029786
[TBL] [Abstract][Full Text] [Related]
34. Management of oral anticoagulant treatment in patients with venous thromboembolism.
Pengo V
Semin Thromb Hemost; 2006 Nov; 32(8):781-6. PubMed ID: 17171590
[TBL] [Abstract][Full Text] [Related]
35. [Problems of long-term therapy with anticoagulants].
Lechner K; Gaiger A; Fritz A; Kyrle P; Eichinger S; Pabinger I
Acta Med Austriaca; 1992; 19(1):21-4. PubMed ID: 1585783
[TBL] [Abstract][Full Text] [Related]
36. [Long-term follow-up in patients receiving anticoagulation therapy: potency of therapy and complications].
Katsuki T; Saito M; Noda T; Yaginuma T; Hosoda S
J Cardiol; 1994; 24(3):203-9. PubMed ID: 8207635
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes.
Bloomfield HE; Krause A; Greer N; Taylor BC; MacDonald R; Rutks I; Reddy P; Wilt TJ
Ann Intern Med; 2011 Apr; 154(7):472-82. PubMed ID: 21464349
[TBL] [Abstract][Full Text] [Related]
38. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
[TBL] [Abstract][Full Text] [Related]
40. High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Heras M; Chesebro JH; Fuster V; Penny WJ; Grill DE; Bailey KR; Danielson GK; Orszulak TA; Pluth JR; Puga FJ
J Am Coll Cardiol; 1995 Apr; 25(5):1111-9. PubMed ID: 7897124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
